Positioned for the Future

Research and Development

We have an innovative and vibrant research program for developing novel methodologies for pre-clinical evaluation of drugs, toxicants and other chemicals. Our scientists aim at discovering technologies that will accelerate metabolism and toxicity testing and accurately predict the human response to drugs. In Vitro ADMET Laboratories has prioritized its research and development efforts in the following areas:


The goal is to develop robust, high-throughput and validated in vitro models for testing drugs that can be used to treat neurological disorders or chemicals that may cause neurotoxicity.

Model for the Blood Brain Barrier:

Recent estimates indicate that 98% of small molecules intended for therapeutic use in nervous system disorders never actually reach the market because of their inability to cross the blood brain barrier. Considering that there are about 80 million individuals with brain disorders, such as Parkinson’s and Alzheimer’s diseases, the need for a model to assess permeability of drugs is immense. Our scientists are working hard to develop and optimize an in vitro model using animal and human primary cells that will address this unmet need.

Model for Neurotoxicity:

Thousands of chemicals including household products, agricultural pesticides, as well as food and drug constituents should be tested for potential toxicity to the nervous system. IVAL is committed to developing accurate models that are physiologically relevant and can recapitulate processes such as proliferation, differentiation and metabolism within the brain. Such systems capable of reproducible, high throughput screening are currently under development.


Diabetes affects approximately 170 million individuals worldwide and is ever increasing. The rising incidence of obesity perpetuates the need for anti-diabetic medications and emphasizes the need for physiologically relevant models for drug testing. IVAL is currently developing diabetic models using human hepatocytes, pancreatic islet cells and adipocytes using IdMOC technology.

Chronic Liver Infection by the Hepatitis C Virus:

The Hepatitis C Virus (HCV) causes persistent infection of the liver and is currently treated with Peginterferon and Ribavirin. However the curative rate is only 51%. An estimated 250 million individuals are known to be infected with HCV worldwide. IVAL is dedicated to developing an in vitro model using human primary cells for testing therapeutic drugs against HCV infection.